Tandem Diabetes Care (TNDM) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 sales of $244.0 million (GAAP), up 31% year-over-year, driven by strong execution, new product launches, and higher pump shipments in both U.S. and international markets.

• Returned to positive free cash flow and adjusted EBITDA, with significant growth from MDI users converting to pumps and robust international pump placements.

• Gross margin improved to 51% from 48% year-over-year, benefiting from pricing improvements and product mix, despite higher labor and overhead costs.

• Net loss for Q3 2024 was $23.3M, or $(0.35) per share, narrowing from the prior year, as higher gross profit offset increased SG&A and R&D expenses.

• Completed pivotal clinical study for Control-IQ expansion to type 2 diabetes; regulatory submission expected by year-end.

Financial highlights

• Q3 2024 worldwide sales reached $244.0M (GAAP), with U.S. sales at $171.7M (up 23%) and OUS sales at $72.3M (up 31%).

• Gross margin was 51% in Q3; GAAP gross profit $124.7M; adjusted EBITDA margin 2% of sales.

• Operating loss for Q3 2024 was $26.1M; net loss $23.3M; EPS $(0.35).

• Cash and investments at quarter end were $473.3M.

• Cash flow from operations for nine months ended September 30, 2024: $13.5M provided.

Outlook and guidance

• Raised full-year 2024 sales guidance to $903M–$910M, with U.S. sales expected at $645M–$650M and OUS at $258M–$260M.

• Reaffirmed full-year gross margin expectation of 51% and adjusted EBITDA breakeven.

• Management expects cash and investments plus future cash flows to fund ongoing business activities for at least the next 12 months.

• The Tandem Choice program will continue to impact financials until its conclusion at year-end 2024, with deferred revenue to be recognized in Q4.

• Q1 2025 expected to show typical seasonality with a step down in sales and profits from Q4.